Recent treatment guidelines for managing adult patients with sickle cell disease: challenges in access to care, social issues, and adherence

Expert Review of Hematology

Volumn 9, Issue 6, 2016, Pages 541-552

  Adams Graves, Patricia ^a   Bronte Jordan, Lanetta ^b,c  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c Foundation for Sickle Cell Disease Research   (United States)

Author keywords

Adult; guidelines; hospitalization; sickle cell complications; sickle cell disease; transition

Indexed keywords

HYDROXYUREA; IRON CHELATING AGENT;

ACUTE CHEST SYNDROME; ADULT; ADULT DISEASE; BONE NECROSIS; CEREBROVASCULAR ACCIDENT; CLINICAL FEATURE; COMORBIDITY; EMERGENCY WARD; FERTILITY; HEALTH CARE ACCESS; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH DISPARITY; HOSPITAL PATIENT; HOSPITAL READMISSION; HOSPITALIZATION; HUMAN; IRON CHELATION; IRON OVERLOAD; KIDNEY DISEASE; LEG ULCER; LIVER DISEASE; MAINTENANCE THERAPY; MORTALITY; MULTICENTER STUDY (TOPIC); PATIENT COMPLIANCE; PRACTICE GUIDELINE; PREGNANCY; PRIAPISM; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SICKLE CELL ANEMIA; SOCIOECONOMICS; TRANSITION TO ADULT CARE; YOUNG ADULT; AGE; ANALGESIA; ANEMIA, SICKLE CELL; COMPLICATION; DISEASE MANAGEMENT; HEALTH CARE DELIVERY; HEALTH CARE DISPARITY; HEALTH CARE QUALITY; PAIN; PHENOTYPE; PROGNOSIS; PROTOCOL COMPLIANCE; TREATMENT OUTCOME;

ADULT; AGE FACTORS; ANEMIA, SICKLE CELL; COMORBIDITY; DISEASE MANAGEMENT; GUIDELINE ADHERENCE; HEALTH SERVICES ACCESSIBILITY; HEALTHCARE DISPARITIES; HUMANS; MORTALITY; PAIN; PAIN MANAGEMENT; PHENOTYPE; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; QUALITY INDICATORS, HEALTH CARE; SOCIOECONOMIC FACTORS; TREATMENT OUTCOME;

EID: 84975257632     PISSN: 17474086     EISSN: 17474094     Source Type: Journal    
DOI: 10.1080/17474086.2016.1180242     Document Type: Review

References (104)

1. P.Adams-Graves, E.J.Ostric, M.Martin, et al. Sickle cell hospital unit: a disease-specific model. J Healthc Manag. 2008;53:305–315.
2. D.C.Brousseau, J.A.Panepinto, M.Nimmer, et al. The number of people with sickle-cell disease in the United States: national and state estimates. Am J Hematol. 2010;85:77–78.
3. K.L.Hassell Population estimates of sickle cell disease in the U.S. Am J Prev Med. 2010;38(4):S512–521.
4. O.S.Platt, D.J.Brambilla, W.F.Rosse, et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med. 1994;330:1639–1644.
5. S.Lanzkron, C.P.Carroll, C.HaywoodJr. Mortality rates and age at death from sickle cell disease: U.S., 1979–2005. Public Health Rep. 2013;128:110–116.
6. S.T.Paulukonis, J.R.Eckman, A.B.Snyder, et al. Defining sickle cell disease mortality using a population-based surveillance system, 2004 through 2008. Public Health Rep. 2016;131:367–375.
7. Evidence-Based Management of Sickle Cell Disease. Expert Panel Report, 2014. National Institutes of Health. National Heart, Lung, and Blood Institute, 2014. [cited 2015 Sep 28]. Available from: http://www.nhlbi.nih.gov/health-pro/guidelines/sickle-cell-disease-guidelines.•• Provides much needed, evidence-based guidelines for management of SCD.
8. B.P.Yawn, G.R.Buchanan, A.N.Afenyi-Annan, et al. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. JAMA. 2014;312:1033–1048.•• Provides much needed, evidence-based guidelines for management of SCD.
9. K.A.Neville, J.A.Panepinto. Pharmacotherapy of sickle cell disease. World Health Organization: 18th Expert Committee on the Selection and Use of Essential Medicines, 2011 Mar 21–25. [cited 2015 Sep28]. Available from: http://www.who.int/selection_medicines/committees/expert/18/applications/Sicklecell.pdf.
10. Sickle Cell Society. Standards for the clinical care of adults with sickle cell disease in the UK. London: Sickle Cell Society; 2008.
11. The Management of Sickle Cell Disease. Revised June 2002. NIH Publication No. 02–2117. Bethesda (MD): National Institutes of Health. National Heart, Lung, and Blood Institute. [cited 2015 Sep28]. Available from: http://www.nhlbi.nih.gov/health/prof/blood/sickle/sc_mngt.pdf.
12. S.Charache, M.L.Terrin, R.D.Moore, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N Engl J Med. 1995;332:1317–1322.
13. O.W.Brawley, L.J.Cornelius, L.R.Edwards, et al. National Institutes of Health Consensus Development Conference statement: hydroxyurea treatment for sickle cell disease. Ann Intern Med. 2008;148:932–938.
14. E.S.Klings, R.F.Machado, R.J.Barst, et al. American Thoracic Society ad hoc committee on pulmonary hypertension of sickle cell disease. An official American Thoracic Society clinical practice guideline: diagnosis, risk stratification, and management of pulmonary hypertension of sickle cell disease. Am J Respir Crit Care Med. 2014;189:727–740.
15. Centers for Disease Control and Prevention. Prevention and control of Haemophilus influenzae type b disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2014;63(RR–01):1–14.
16. Centers for Disease Control and Prevention. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2012;61:816–889.
17. Centers for Disease Control and Prevention. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2013;62(RR–2):1–28.
18. Social Security Disability Help. Sickle cell disease and Social Security disability. 2016. [cited 2016 Apr4] Available from: http://www.disability-benefits-help.org/disabling-conditions/sickle-cell-disease-and-social-security-disability.
19. Social Security Disability. 2016. [cited 2016 Apr4]. Available from https://www.disability.gov.
20. E.Labbé, D.Herbert, J.Haynes. Physicians’ attitude and practices in sickle cell disease pain management. J Palliat Care. 2005;21:246–251.
21. S.K.Ballas, M.Lusardi. Hospital readmission for adult acute sickle cell painful episodes: frequency, etiology, and prognostic significance. Am J Hematol. 2005;79:17–25.
22. S.K.Ballas. Sickle cell pain. 2nd ed. Seattle (WA): IASP Press; 2014.
23. S.K.Ballas, K.Gupta, P.Adams-Graves. Sickle cell pain: a critical reappraisal. Blood. 2012;120:3647–3656.
24. W.R.Smith, L.T.Penberthy, V.E.Bovbjerg, et al. Daily assessment of pain in adults with sickle cell disease. Ann Intern Med. 2008;148:94–101.
25. O.S.Platt, B.D.Thorington, D.J.Brambilla, et al. Pain in sickle cell disease. Rates and risk factors. N Engl J Med. 1991;325:11–16.
26. J.Kanter, R.Kruse-Jarres. Management of sickle cell disease from childhood through adulthood. Blood Rev. 2013;27:279–287.
27. C.J.Bean, W.C.Hooper, D.Ellingsen, et al. Discordance between self-report and genetic confirmation of sickle cell disease status in African-American adults. Public Health Genomics. 2014;17:169–172.
28. J.J.Strouse, L.C.Jordan, S.Lanzkron, et al. The excess burden of stroke in hospitalized adults with sickle cell disease. Am J Hematol. 2009;84:548–552.
29. A.Gueguen, M.Mahevas, R.Nzouakou, et al. Sickle-cell disease stroke throughout life: a retrospective study in an adult referral center. Am J Hematol. 2014;89:267–272.
30. E.O.Gosmanova, S.Zaidi, J.Y.Wan, et al. Prevalence and progression of chronic kidney disease in adult patients with sickle cell disease. J Investig Med. 2014;62:804–807.
31. A.C.McClellan, J.C.Luthi, J.R.Lynch, et al. High one year mortality in adults with sickle cell disease and end-stage renal disease. Br J Haematol. 2012;159:360–367.
32. E.P.Vichinsky, L.A.Styles, L.H.Colangelo, et al. Acute chest syndrome in sickle cell disease: clinical presentation and course. Cooperative Study of Sickle Cell Disease. Blood. 1997;89:1787–1792.
33. A.Mehari, S.Alam, X.Tian, et al. Hemodynamic predictors of mortality in adults with sickle cell disease. Am J Respir Crit Care Med. 2013;187:840–847.
34. M.T.Gladwin, V.Sachdev, M.L.Jison, et al. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med. 2004;350:886–895.
35. M.Koshy, R.Entsuah, A.Koranda, et al. Leg ulcers in patients with sickle cell disease. Blood. 1989;74:1403–1408.
36. K.M.Delaney, K.C.Axelrod, A.Buscetta, et al. Leg ulcers in sickle cell disease: current patterns and practices. Hemoglobin. 2013;37:325–332.
37. P.A.Berry, T.J.Cross, S.L.Thein, et al. Hepatic dysfunction in sickle cell disease: a new system of classification based on global assessment. Clin Gastroenterol Hepatol. 2007;5:1469–1476.
38. N.Alayed, A.Kezouh, L.Oddy, et al. Sickle cell disease and pregnancy outcomes: population-based study on 8.8 million births. J Perinat Med. 2014;42:487–492.
39. I.Berthaut, G.Guignedoux, F.Kirsch-Noir, et al. Influence of sickle cell disease and treatment with hydroxyurea on sperm parameters and fertility of human males. Haematologica. 2008;93:988–993.
40. E.Mantadakis, J.D.Cavender, Z.R.Rogers, et al. Prevalence of priapism in children and adolescents with sickle cell anemia. J Pediatr Hematol Oncol. 1999;21:518–522.
41. A.B.Adeyoju, A.B.Olujohungbe, J.Morris, et al. Priapism in sickle-cell disease; incidence, risk factors and complications – an international multicentre study. BJU Int. 2002;90:898–902.
42. J.R.SharpsteenJr, D.Powars, C.Johnson, et al. Multisystem damage associated with tricorporal priapism in sickle cell disease. Am J Med. 1993;94:289–295.
43. P.F.Milner, A.P.Kraus, J.I.Sebes, et al. Sickle cell disease as a cause of osteonecrosis of the femoral head. N Engl J Med. 1991;325:1476–1481.
44. V.Allareddy, A.Roy, M.K.Lee, et al. Outcomes of acute chest syndrome in adult patients with sickle cell disease: predictors of mortality. PLoS One. 2014;9:e94387.
45. H.Elmariah, M.E.Garrett, L.M.De Castro, et al. Factors associated with survival in a contemporary adult sickle cell disease cohort. Am J Hematol. 2014;89:530–535.• A large adult cohort study on SCD mortality factors.
46. M.T.Gladwin, R.J.Barst, J.S.Gibbs, et al. Walk-PHaSST investigators and patients. Risk factors for death in 632 patients with sickle cell disease in the United States and United Kingdom. PLoS One. 2014;9:e99489.
47. D.S.Darbari, Z.Wang, M.Kwak, et al. Severe painful vaso-occlusive crises and mortality in a contemporary adult sickle cell anemia cohort study. PLoS One. 2013;8:e79923.
48. M.H.Steinberg, W.F.McCarthy, O.Castro, et al. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia and MSH patients’ follow-up. The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: a 17.5 year follow-up. Am J Hematol. 2010;85:403–408.
49. N.F.Olivieri. Progression of iron overload in sickle cell disease. Semin Hematol. 2001;38(1 Suppl 1):57–62.
50. A.Meloni, M.Puliyel, A.Pepe, et al. Cardiac iron overload in sickle-cell disease. Am J Hematol. 2014;89:678–683.
51. S.K.Ballas. Iron overload is a determinant of morbidity and mortality in adult patients with sickle cell disease. Semin Hematol. 2001;38(1 Suppl 1):30–36.
52. N.C.Andrews. Disorders of iron metabolism. N Engl J Med. 1999;341:1986–1995.
53. J.B.Porter. Practical management of iron overload. Br J Haematol. 2001;115:239–252.
54. J.Kanter, R.Kruse-Jarres. Management of sickle cell disease from childhood through adulthood. Blood Rev. 2013;27:279–287.
55. D.S.Darbari, P.Kple-Faget, J.Kwagyan, et al. Circumstances of death in adult sickle cell disease patients. Am J Hematol. 2006;81:858–863.
56. D.T.Kremastinos, G.A.Tsetsos, D.P.Tsiapras, et al. Heart failure in beta thalassemia: a 5-year follow-up study. Am J Med. 2001;111:349–354.
57. D.J.Pennell, J.E.Udelson, A.E.Arai, et al. American Heart Association Committee on Heart Failure and Transplantation of the Council on Clinical Cardiology and Council on Cardiovascular Radiology and Imaging. Cardiovascular function and treatment in β-thalassemia major: a consensus statement from the American Heart Association. Circulation. 2013;128:281–308.
58. 2013 National Healthcare Disparities Report. AHRQ Publication No. 14–0006. Agency for Healthcare Research and Quality. [updated 2014 May; cited 2015 Sep28]. Available from: http://www.ahrq.gov/research/findings/nhqrdr/index.html.
59. Centers for Disease Control and Prevention. CDC health disparities and inequalities report – United States, 2011. MMWR. 2011;60(Suppl):1–113.
60. Centers for Disease Control and Prevention. CDC health disparities and inequalities report – United States, 2013. MMWR. 2013;62(Suppl 3):1–186.
61. J.A.Wolfson, S.M.Schrager, R.Khanna, et al. Sickle cell disease in California: sociodemographic predictors of emergency department utilization. Pediatr Blood Cancer. 2012;58:66–73.
62. J.Telfair, A.Haque, M.Etienne, et al. Rural/urban differences in access to and utilization of services among people in Alabama with sickle cell disease. Public Health Rep. 2003;118:27–36.
63. M.A.Blinder, F.Vekeman, M.Sasane, et al. Age-related treatment patterns in sickle cell disease patients and the associated sickle cell complications and healthcare costs. Pediatr Blood Cancer. 2013;60:828–835.•• Provides information on the costs borne by adult patients with SCD.
64. C.A.Boyle, J.N.Gracia. Changing the prognosis for sickle cell disease through the Affordable Care Act. [updated 2013 Sep 27; cited 2015 Sep28]. Blog: National Partnership for Action. Available from: http://www.minorityhealth.hhs.gov/npa/blog/BlogPost.aspx?BlogType=P&BlogID=3016.
65. S.C.Nelson, H.W.Hackman. Race matters: perceptions of race and racism in a sickle cell center. Pediatr Blood Cancer. 2013;60:451–454.
66. C.HaywoodJr, M.Diener-West, J.Strouse, et al. IMPORT Investigators. Perceived discrimination in health care is associated with a greater burden of pain in sickle cell disease. J Pain Symptom Manage. 2014;48:934–943.
67. C.HaywoodJr, S.Bediako, S.Lanzkron, et al. For the IMPORT Investigators. An unequal burden: poor patient–provider communication and sickle cell disease. Patient Educ Couns. 2014;96:159–164.
68. A.P.Wilper, S.Woolhandler, K.E.Lasser, et al. Waits to see an emergency department physician: U.S. trends and predictors, 1997–2004. Health Aff (Millwood). 2008;27:w84–w95.
69. C.HaywoodJr, P.Tanabe, R.Naik, et al. The impact of race and disease on sickle cell patient wait times in the emergency department. Am J Emerg Med. 2013;31:651–656.
70. HHS Announces Sickle Cell Disease Initiative. Bethesda (MD): National Institutes of Health. National Heart, Lung, and Blood Institute, Office of the Director. 2011. [cited 2015 Sep28]. Available from: http://www.nhlbi.nih.gov/about/directorscorner/messages/2009-2012-shurin/hhs-announces-sickle-cell-disease-initiative.html#.
71. Sickle Cell Disease, About Us. Centers for Disease Control and Prevention. National Center on Birth Defects and Developmental Disabilities (NCBDDD), 2014. [cited 29Sep 2015]. Available from: http://www.cdc.gov/ncbddd/sicklecell/about.html.
72. Sickle Cell Disease, Data & Statistics. Centers for Disease Control and Prevention. National Center on Birth Defects and Developmental Disabilities (NCBDDD), 2015. [cited 2015 Sep29]. Available from: http://www.cdc.gov/ncbddd/sicklecell/data.html.
73. RuSH Strategies From the Field: Data Collection. Centers for Disease Control and Prevention. National Center on Birth Defects and Developmental Disabilities (NCBDDD), 2014. [cited 29Sep 2015]. Available from: http://www.cdc.gov/ncbddd/hemoglobinopathies/rush.html.
74. T.L.Kauf, T.D.Coates, L.Huazhi, et al. The cost of health care for children and adults with sickle cell disease. Am J Hematol. 2009;84:323–327.
75. M.A.Blinder, M.Sasane, J.Fortier, et al. High cost patients and cost patterns from pediatric to adult care in a Medicaid population with sickle cell disease. Presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 19th Annual International Meeting; 2014 May 31–June 4; Montreal, QC. Abstract PHS71.
76. C.A.Steiner, J.L.Miller. Sickle Cell Disease Patients in U.S. Hospitals, 2004. HCUP Statistical Brief #21. December 2006. Agency for Healthcare Research and Quality, Rockville, MD. [cited 2015 Sep29]. Available from: http://www.hcup-us.ahrq.gov/reports/statbriefs/sb21.pdf.
77. D.C.Brousseau, P.L.Owens, A.L.Mosso, et al. Acute care utilization and rehospitalizations for sickle cell disease. JAMA. 2010;303:1288–1294.• Information on young adult SCD population across several states.
78. S.D.Candrilli, S.H.O’Brien, R.E.Ware, et al. Hydroxyurea adherence and associated outcomes among Medicaid enrollees with sickle cell disease. Am J Hematol. 2011;86:273–277.
79. F.Vekeman, M.Sasane, W.Y.Cheng, et al. Adherence to iron chelation therapy and associated healthcare resource utilization and costs in Medicaid patients with sickle cell disease and thalassemia. J Med Econ. 2016;19:292–303.
80. J.Thakkar, R.Kurup, T.L.Laba, et al. Mobile telephone text messaging for medication adherence in chronic disease: a meta-analysis. JAMA Intern Med. 2016;176:340–349.
81. E.Vichinsky, O.Onyekwere, J.Porter, et al. A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. Br J Haematol. 2007;136:501–508.
82. Novartis Pharmaceuticals Corporation. Exjade [prescribing information]. East Hanover (NJ): Novartis Pharmaceuticals Corporation; 2013.
83. E.P.Armstrong, G.H.Skrepnek, M.Sasane, et al. Long-term persistency and costs associated with the use of iron chelation therapies in the treatment of sickle cell disease within Medicaid programs. J Med Econ. 2013;16:10–18.
84. L.B.Jordan, F.Vekeman, A.Sengupta, et al. Persistence and compliance of deferoxamine versus deferasirox in Medicaid patients with sickle-cell disease. J Clin Pharm Ther. 2012;37:173–181.
85. M.McManus, D.Beck, P.White. The National Alliance to Advance Adolescent Health. 2016. [cited 2016 Apr4]. Available from http://www.gottransition.org/resourceGet.cfm?id=407.
86. C.P.Williams, C.H.Smith, K.Osborn, et al. Patient-centered approach to designing sickle cell transition education. J Pediatr Hematol Oncol. 2015;37:43–47.• Provides information on transitioning patients’ knowledge and level of interest in disease education.
87. A.Sobota, A.Akinlonu, M.Champigny, et al. Self-reported transition readiness among young adults with sickle cell disease. J Pediatr Hematol Oncol. 2014;36:389–394.
88. B.Andemariam, J.Owarish-Gross, J.Grady, et al. Identification of risk factors for an unsuccessful transition from pediatric to adult sickle cell disease care. Pediatr Blood Cancer. 2014;61:697–701.
89. J.S.Hankins, R.Osarogiagbon, P.Adams-Graves, et al. A transition pilot program for adolescents with sickle cell disease. J Pediatr Health Care. 2012;26:e45–49.
90. C.M.Jenerette, C.A.Brewer, L.J.Edwards, et al. An intervention to decrease stigma in young adults with sickle cell disease. West J Nurs Res. 2014;36:599–619.
91. W.C.Cooley, P.J.Sagerman, American Academy of Pediatrics, American Academy of Family Physicians, and American College of Physicians; Transitions Clinical Report Authoring Group. Supporting the health care transition from adolescence to adulthood in the medical home. Pediatrics. 2011;128:182–200.
92. M.R.DeBaun, J.Telfair. Transition and sickle cell disease. Pediatrics. 2012;130:926–935.
93. S.D.Grosse, M.S.Schechter, R.Kulkarni, et al. Models of comprehensive multidisciplinary care for individuals in the United States with genetic disorders. Pediatrics. 2009;123:407–412.
94. L.E.Crosby, C.T.Quinn, K.A.Kalinyak. A biopsychosocial model for the management of patients with sickle-cell disease transitioning to adult medical care. Adv Ther. 2015;32:293–305.
95. L.J.Benjamin, G.I.Swinson, R.L.Nagel. Sickle cell anemia day hospital: an approach for the management of uncomplicated painful crises. Blood. 2000;95:1130–1136.
96. L.Jordan. AHRQ Health Care Innovations Exchange. Day hospital reduces inpatient length of stay and emergency department visits for patients with sickle cell anemia, 2011. [cited 2015 Sep29]. Available from: https://innovations.ahrq.gov/profiles/day-hospital-reduces-inpatient-length-stay-and-emergency-department-visits-patients-sickle.
97. D.J.Wilkie, B.Johnson, A.K.Mack, et al. Sickle cell disease: an opportunity for palliative care across the life span. Nurs Clin North Am. 2010;45:375–397.
98. Grady Health. Sickle Cell Center. [cited 2015 Sep29]. Available from: http://www.gradyhealth.org/specialty/sickle-cell-center.html.
99. K.L.Koch, M.S.Karafin, P.Simpson, et al. Intensive management of high-utilizing adults with sickle cell disease lowers admissions. Am J Hematol. 2015;90:215–219.
100. S.Lanzkron, C.P.Carroll, P.Hill, et al. Impact of a dedicated infusion clinic for acute management of adults with sickle cell pain crisis. Am J Hematol. 2015;90:376–380.
101. L.N.Whiteman, S.Lanzkron, R.W.Stewart, et al. Quality improvement process in a sickle cell infusion center. Am J Med. 2015;128:541–544.
102. L.Jordan. Day hospital reduces inpatient length of stay and emergency department visits for patients with sickle cell anemia. AHRQ Innovations Exchange. 2011. [cited 2016 Mar24]. Available from: http://www.innovations.ahrq.gov/content.aspx?id=3100.2011a.
103. L.Jordan. Sickle cell day hospital, a solution that works. National Association of Public Hospitals and Health Systems. 2011. [cited 2016 Mar24]. Available from http://naph.org/Homepage%20Sections/Explore/Innovations/CareCoordination/Memorial-Regional-Hospital-Sickle-CellInnovation.aspx.2011b.
104. K.R.Lorig, P.Ritter, A.L.Stewart, et al. Chronic disease self-management program: 2-year health status and health care utilization outcomes. Med Care. 2001;39:1217–1223.